Register for the Conference HERE BEBPA’s 5 th Annual US Bioassay Conference Best Pracces for the Best Potency Assays March 22-25, 2021 3 Ways to Register: Online at BEBPA.org – Phone: 206-651-4542 – Email: [email protected] Day 1: Monday, March 22, 2021 Regulatory Insights and Potency Method Development Day 2: Tuesday, March 23, 2021 Method Development Tools Day 3: Wednesday, March 24, 2021 Reference Standards for Potency Assays Day 4: Thursday, March 25, 2021 Potency Assay Development for Complex Products *All Times are in US PACIFIC DAYLIGHT TIME* Session Chair: Laureen Lile, President, BEBPA 7:30-7:35: Welcome Comments by BEBPA’s President 7:35-7:45: Session Introducon & Audience Survey 7:45-8:15: Switching from In-Vivo to In-Vitro Assays: A Reviewer’s Perspecve Leslie Wagner, Chemist, FDA 8:15-8:30: Q & A Session 8:30-9:00: A Reviewer’s Perspecve on Bioassay Development in 2021 Gerald Feldman, Office of Biotechnology Products, FDA 9:00-9:15: Q & A Session 9:15 - 9:30 Break 9:30-10:00: Design of Experiments for the Validaon of Potency Assays Perceval Sondag, Director of Data Science, Merck 10:00-10:15: Q&A Session 10:15-10:45: Implementaon of Acousc Droplet Ejecon Technology in Quality Control Potency Tesng Jill Crouse-Zeineddini, Scienfic Director, Amgen Inc. 10:45-11:15: Panel Discussion 11:20-12:00: Round Table - Discussion Topics: • Rapid Fire Talks: Complex Product Bioassays (Krisn Clement) Potency Assay Cell Therapy talk (Katherine Matsuda) Promega (Jey Cheng) • Potency Assays for mAb (Mike Merges) • Bioassays for Vaccine Products (Bassam Hallis) • Rapid Fire Talks: Soluons for Potency Assays (Mike Sadick) Brendan Bioanalycs (John Dunn) ImmunXperts (Sofie Payn) Svar (Michael Tovey) 12:00 Conference Adjourns Session Chair: Nancy Niemuth, Research Leader, Baelle 7:30-7:45: Session Introducon & Audience Survey 7:45-8:15: Stascal Model Selecon Using USP <1034> Steven Walfish, Principal Liaison, USP 8:15-8:30: Q & A Session 8:30-9:00: Mixed Model Bioassay Analysis: How & Why David Lansky, President, Precision Bioassay 9:00-9:15: Q & A Session 9:15 - 9:30 Break 9:30-10:00: Why We Like the 15PL Stan Deming, President, Stascal Designs 10:00-10:15: Q & A Session 10:15-10:45: Potency Assays for Phase I/II Cell and Gene Therapy Products: Experiences for a Small “CMO” Within an Academic Instuon Sco Wing, Director, Translaonal Trials Support and Developmental Laboratory (TTSDL) Cincinna Children’s Hospital Medical Center 10:45-11:00: Q & A Session 11:00-11:45: Panel Discussion 11:45 Conference Adjourns Session Chair: Sian Estdale, Head of Scienfic Affairs, Covance 7:30-7:45: Session Introducon & Audience Survey 7:45-8:15: Handling Product References for Potency Assays: A Review of the BEBPA White Paper Laureen Lile, President, BEBPA 8:15-8:30: Q & A Session 8:30-9:00: Why the Reference Standard is so Important to Potency Assays Mena Odocayen, Senior Research Associate, Genentech 9:00-9:15: Q & A Session 9:15 - 9:30 Break 9:30-10:00: A Lesson from Monitoring Reference Standard Stability Gareth Rees, Senior QA Biological Specialist, Porton Biopharma Limited 10:00-10:15: Q & A Session 10:15-10:45: CEPI Centralized Laboratory Network for Measurement of Immune Responses Elicited by SARS-CoV-2 Vaccines Valenna Bernasconi, Scienst, CEPI 10:45-11:15: Panel Discussion 11:20-12:00: Round Tables - Discussion Topics: • Reference Material: Connued (Seth Foltz) • Replacing a Potency Assay (Sian Estdale) • Validaon Strategies (David Lansky) • Advance Analysis for Potency, LBA and IMG Assays (John Dunn) 12:00 Conference Adjourns Session Chair: Krisn Clement, Principal Consultant, Bio-Val Consulng 7:30-7:45: Session Introducon & Audience Survey 7:45-8:15: Translang the USP for Cell-Based Gene Therapy Methods Catherine Liloia, Director, PPD 8:15-8:30: Q & A Session 8:30-9:00: Evaluaon of a Cell-Based Potency Assay to Support Clinical Development of an Amnioc-Derived Biologic for the Treatment of Osteoarthris Miranda Burnee, Senior Scienst, Organogenesis 9:00-9:15: Q & A Session 9:15 - 9:30 Break 9:30-10:00: Potency Bioassay Strategies for Gene Therapy Programs Savita Sankar, Principal Scienst, Pfizer 10:00-10:15: Q & A Session 10:15-10:45: Assessing Stability-Indicang Methods of a CAR T Cellular Therapy Mel Davis-Picke, Senior Associate Scienst, Bristol Myers Squibb 10:45-11:00: Q & A Session 11:00-11:45: Panel Discussion 11:45 Conference Adjourns Thank You Conference Sponsors! *Slides not available for distribuon are highlighted in RED* PDT SGT CDT EDT GMT CET KST